TREATMENT OF COPD CONSIDERING NEUTROPHILIC AND EOSINOPHILIC TYPES OF INFLAMMATION: PATHOGENETIC APPROACH AND ROLE OF THE DERKAST (YURIA-PHARM)
Acta Medica Leopoliensia · 22.12.2025 · 31 (3-4) · 128-137
DOI: 10.25040/aml2025.3-4.128 ↗Kurz gefasst
Fachartikel in der Zeitschrift Acta Medica Leopoliensia, online erschienen am 22.12.2025. Verfasst von Khrystyna Volnytska und 3 weiteren Autor:innen. Die Arbeit nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: COPD
Abstract (Originalsprache)
The aim of the study was to analyze the effectiveness of the use of Derkast in complex treatment at the hospital stage in patients with moderate and severe exacerbations of COPD, taking into account the inflammatory phenotype. Material and Methods. Access to full-text and abstract databases and scientific publications was used. Results and Discussion. According to the provisions of GOLD (2024-2025), the leading role in the pathogenesis of destabilization of the course and development of exacerbations of COPD is played by the inflammatory process in the respiratory tract and increased bronchoconstriction. Inflammation may be eosinophilic or neutrophilic (often resistant to ICS), therefore, there is insufficient effectiveness of standard therapy depending on the phenotypes of inflammation. Therefore, the use of the new domestic drug Derkast, which is a FED inhibitor, can provide comprehensive treatment for the relief of COPD exacerbations at the hospital stage. Derkast, by inhibiting PDE-3, PDE-4 and PDE-5, promotes the development of bronchodilator and anti-inflammatory effects and potentiation of inhaled drugs; moreover, the potassium and magnesium ions included in the preparation provide a rapid and controllable effect of stabilizing the course of COPD in inpatient treatment. Conclusions. A comprehensive approach to the treatment of moderate to severe exacerbations of COPD at the hospital stage using the new domestic drug Derkast, taking into account the phenotype of inflammation, is a pathogenetically justified means of increasing the effectiveness of therapy for this category of patients. The need to prescribe FDE inhibitors in inpatient treatment of this category of patients is caused by a decrease in the sensitivity of b2-adrenoreceptors to short-acting b2-adrenomimetics due to their uncontrolled and frequent use, which leads to an increase in chronic persistent inflammation and the development of exacerbations.
Zitieren
APA
Volnytska, K., Ostrovskyi, M., Kostyk, O., & Rudnytska, N. (2025). TREATMENT OF COPD CONSIDERING NEUTROPHILIC AND EOSINOPHILIC TYPES OF INFLAMMATION: PATHOGENETIC APPROACH AND ROLE OF THE DERKAST (YURIA-PHARM). Acta Medica Leopoliensia, 31(3-4), 128-137. https://doi.org/10.25040/aml2025.3-4.128
Vancouver
Volnytska K, Ostrovskyi M, Kostyk O, Rudnytska N. TREATMENT OF COPD CONSIDERING NEUTROPHILIC AND EOSINOPHILIC TYPES OF INFLAMMATION: PATHOGENETIC APPROACH AND ROLE OF THE DERKAST (YURIA-PHARM). Acta Medica Leopoliensia. 2025;31(3-4):128-137. doi:10.25040/aml2025.3-4.128
BibTeX
@article{Volnytska2025,
author = {Volnytska, Khrystyna and Ostrovskyi, Mykola and Kostyk, Olga and Rudnytska, Nadija},
title = {TREATMENT OF COPD CONSIDERING NEUTROPHILIC AND EOSINOPHILIC TYPES OF INFLAMMATION: PATHOGENETIC APPROACH AND ROLE OF THE DERKAST (YURIA-PHARM)},
journal = {Acta Medica Leopoliensia},
year = {2025},
volume = {31},
number = {3-4},
pages = {128--137},
doi = {10.25040/aml2025.3-4.128}
}
EUVIMED